Get the Stockscreener App
0.8597
4.46%
-0.0401
Pre-market:
.82
-0.0397
-4.62%
Lucid Diagnostics Inc stock is traded at $0.8597, with a volume of 279.94K.
It is down -4.46% in the last 24 hours and up +5.61% over the past month.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
See More
Previous Close:
$0.8998
Open:
$0.897
24h Volume:
279.94K
Relative Volume:
0.62
Market Cap:
$51.02M
Revenue:
$2.43M
Net Income/Loss:
$-52.67M
P/E Ratio:
-0.6823
EPS:
-1.26
Net Cash Flow:
$-33.04M
1W Performance:
+8.27%
1M Performance:
+5.61%
6M Performance:
+2.47%
1Y Performance:
-41.91%
1-Day Range:
$0.8514
$0.9028
1-Week Range:
$0.7803
$0.9094
52-Week Range:
$0.6301
$1.58
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Name
Lucid Diagnostics Inc
Sector
Industry
Phone
212 949 4319
Address
360 MADISON AVENUE, NEW YORK
Compare LUCD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.8597 | 51.02M | 2.43M | -52.67M | -33.04M | -1.26 |
|
ABT
Abbott Laboratories
|
114.25 | 198.16B | 41.22B | 5.77B | 6.49B | 3.29 |
|
BSX
Boston Scientific Corp
|
95.95 | 141.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
364.10 | 138.80B | 21.97B | 3.59B | 3.21B | 9.33 |
|
MDT
Medtronic Plc
|
82.68 | 106.02B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.15 | 43.73B | 6.60B | 4.16B | 490.10M | 6.93 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-21 | Initiated | Ascendiant Capital Markets | Buy |
| Nov-08-21 | Initiated | BTIG Research | Buy |
| Nov-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-08-21 | Initiated | Needham | Buy |
Lucid Diagnostics Inc Stock (LUCD) Latest News
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Quantisnow
Lucid Diagnostics Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Defense World
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - PR Newswire
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
Lucid Diagnostics' SWOT analysis: stock faces challenges amid market potential - Investing.com
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - Morningstar
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Lucid Diagnostics' EsoGuard Shows Breakthrough 85% Compliance Rate in Major Clinical Study - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $7.00 at Ascendiant Capital Markets - Defense World
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - The Eastern Progress Online
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics Secures $21.95M Convertible Note Financing, Extends Cash Runway - StockTitan
Lucid Diagnostics Inc. (NASDAQ:LUCD) Short Interest Down 30.6% in November - MarketBeat
Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements - TipRanks
Head-To-Head Review: Lucid Diagnostics (NASDAQ:LUCD) & DIH Holding US (NASDAQ:DHAI) - Defense World
This Pill-Size Diagnostic Seeks to Prevent Thousands of Esophageal Cancer Deaths - MedCity News
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com
Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com
Lucid Diagnostics' SWOT analysis: stock outlook amid reimbursement progress - Investing.com
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - Morningstar
Lucid Diagnostics Announces Agreement for Sale of Senior Secured Convertible Notes - Defense World
Lucid Diagnostics Inc. announced that it expects to receive $21.75 million in funding - Marketscreener.com
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com
Cantor Fitzgerald cuts Lucid Diagnostics stock target, overweight on challenges - Investing.com Australia
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics (NASDAQ:LUCD) Price Target Lowered to $2.00 at Cantor Fitzgerald - MarketBeat
PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy
Lucid Diagnostics (NASDAQ:LUCD) Provides Business Update and Financial Results - Defense World
Lucid Diagnostics' (LUCD) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Lucid Diagnostics (NASDAQ:LUCD) - MarketBeat
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Lucid Diagnostics reports revenue growth and strategic expansion - Investing.com UK
PAVmed Hits Record $1.2M EsoGuard Revenue in Q3, Up 20% Despite Cash Challenges - StockTitan
Lucid Diagnostics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Lucid Diagnostics Reports Q3 Revenue Growth and Strategic Expansion - TipRanks
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
Needham maintains Buy rating on Lucid Diagnostics shares - Investing.com
Needham maintains Buy rating on Lucid Diagnostics shares By Investing.com - Investing.com UK
Lucid Diagnostics Reports Revenue Growth and Secures Funding - TipRanks
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
Lucid Diagnostics Announces Convertible Notes Exchange Initiative - TipRanks
Lucid Diagnostics (LUCD) Scheduled to Post Earnings on Wednesday - MarketBeat
Lucid Diagnostics Inc Stock (LUCD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.54%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):